Literature DB >> 7964448

Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.

A Uenaka1, T Ono, T Akisawa, H Wada, T Yasuda, E Nakayama.   

Abstract

BALB/c radiation leukemia RL male 1 is an immunogenic tumor. We established bulk and cloned cytotoxic T lymphocyte (CTL) lines from regressor (BALB/c x C57BL/6)F1 (CB6F1) spleen cells that recognized RL male 1 specifically. We then obtained antigen peptide recognized by CTL from RL male 1 by acid extraction. Analysis of the acid extract by reversed-phase high performance liquid chromatography (HPLC) on a semipreparative C18 column revealed that fractions eluted in 23 min (peak a) and 26 min (peak b) showed sensitization activity on the P815 target for specific CTL. On further purification of these fractions by HPLC and direct sequencing by Edman degradation, we identified the CTL-recognizing RL male 1 peptide pRL1a (IPGLPLSL) in peak a and its possible precursor peptide pRL1b (SIIPGLPLSL) in peak b. Sequence homology indicated that these peptides were derived from the 5' untranslated region of c-akt oncogene.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7964448      PMCID： PMC2191716          DOI： 10.1084/jem.180.5.1599

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  48 in total

1.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

2.  A transplantable mast-cell neoplasm in the mouse.

Authors:  T B DUNN; M POTTER
Journal:  J Natl Cancer Inst       Date:  1957-04       Impact factor: 13.506

3.  Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer.

Authors:  D H Margulies; G A Evans; K Ozato; R D Camerini-Otero; K Tanaka; E Appella; J G Seidman
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

4.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 5.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

6.  The roles of CD8+ and CD4+ cells in tumor rejection.

Authors:  H Udono; M Mieno; H Shiku; E Nakayama
Journal:  Jpn J Cancer Res       Date:  1989-07

7.  Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.

Authors:  A S Rosenberg; T Mizuochi; S O Sharrow; A Singer
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

8.  Extracellular processing of peptide antigens that bind class I major histocompatibility molecules.

Authors:  L A Sherman; T A Burke; J A Biggs
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

9.  Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.

Authors:  J Skipper; H J Stauss
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more
  21 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

Authors:  Midori Isobe; Shingo Eikawa; Akiko Uenaka; Yoichi Nakamura; Tetsuo Kanda; Shigeru Kohno; Kiyotaka Kuzushima; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2009-10-01

3.  Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.

Authors:  H Ikeda; N Ohta; K Furukawa; H Miyazaki; L Wang; K Kuribayashi; L J Old; H Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

Authors:  Shingo Eikawa; Mikako Nishida; Shusaku Mizukami; Chihiro Yamazaki; Eiichi Nakayama; Heiichiro Udono
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

Review 5.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 6.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

7.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing.

Authors:  Taketoshi Yamano; Shusaku Mizukami; Shigeo Murata; Tomoki Chiba; Keiji Tanaka; Heiichiro Udono
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

9.  Defining the mechanism(s) of protection by cytolytic CD8 T cells against a cryptic epitope derived from a retroviral alternative reading frame.

Authors:  Melanie R Rutkowski; On Ho; William R Green
Journal:  Virology       Date:  2009-06-18       Impact factor: 3.616

10.  T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

Authors:  Akiko Uenaka; Hisashi Wada; Midori Isobe; Takashi Saika; Kazuhide Tsuji; Eiichi Sato; Shuichiro Sato; Yuji Noguchi; Ryohei Kawabata; Takushi Yasuda; Yuichiro Doki; Hiromi Kumon; Keiji Iwatsuki; Hiroshi Shiku; Morito Monden; Achim A Jungbluth; Gerd Ritter; Roger Murphy; Eric Hoffman; Lloyd J Old; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2007-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.